Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

BACKGROUND: Filgrastim and other granulocyte colony-stimulating factors are recommended to decrease febrile neutropenia (FN) incidence among patients with nonmyeloid cancers undergoing chemotherapy. Data comparing biosimilar filgrastim-sndz with reference filgrastim (filgrastim-ref) are limited outs...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartzberg, Lee S, Lal, Lincy S, Balu, Sanjeev, Campbell, Kim, Brekke, Lee, Elliott, Caitlin, Korrer, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126503/
https://www.ncbi.nlm.nih.gov/pubmed/30214262
http://dx.doi.org/10.2147/CEOR.S168298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126503/
https://www.ncbi.nlm.nih.gov/pubmed/30214262
http://dx.doi.org/10.2147/CEOR.S168298

Ejemplares similares